Table 5 Results of a scenario analysis
From: Economic evaluation of pneumococcal conjugate vaccination in The Gambia
No. | Selected alternative scenarios | ICER (US$ per DALYa averted) | ||
|---|---|---|---|---|
| Â | Â | PCV7 | PCV9 &10 | PCV13 |
1 | Immunity waning (no waning up to age 5, 25% decrease up to age 15, and 50% decrease up to age 30) Serotype replacement (by 25%) No herd immunity | 4,110 | 1,220 | 1,010 |
2 | No Immunity waning Serotype replacement (by 25%) No herd immunity | 3,960 | 1,170 | 970 |
3 | No Immunity waning Serotype replacement (increased incidence of non-primary endpoint pneumonia among vaccinated) No herd immunity | 900 | 650 | 550 |
4 | No Immunity waning No serotype replacement No herd immunity | 670 | 490 | 410 |
5 | No Immunity waning Serotype replacement (increased incidence of non-primary endpoint pneumonia among vaccinated) Herd immunity (assumed incidence decrease by 32%, 32%, 8%, and 18% for individuals aged 5-19 years, 20-39 years, 40-64 years, and 65 years and older) | 830 | 550 | 480 |
6 | No Immunity waning No serotype replacement Herd immunity (assumed incidence decrease by 32%, 32%, 8%, and 18% for individuals aged 5-19 years, 20-39 years, 40-64 years, and 65 years and older) | 630 | 430 | 370 |